# Controlled Correspondence Related to Generic Drug Development - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/guidance-document/controlled-correspondence-related-to-generic-drug-development/55babf6e-6cea-4e6c-80f6-3892feff9aab

> FDA guidance document: Controlled Correspondence Related to Generic Drug Development. Issue date: March 18, 2024. Get complete insights and analysis.

---

## Details

- Title: Controlled Correspondence Related to Generic Drug Development
- Communication Type: Guidance Document
- Product Type: drugs
- Office Name: Center for Drug Evaluation and Research
- Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c
- Issue Date: 2024-03-18
- Last Changed: 2024-03-18
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2014-D-1167">FDA-2014-D-1167</a>

## Related Documents

- [Botanical Drug Development: Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/botanical-drug-development-guidance-for-industry/bec78068-96c3-424e-b070-7b4ecfcfc8bf)
- [Competitive Generic Therapies](https://www.globalkeysolutions.net/guidances/guidance-document/competitive-generic-therapies/402bfb2a-4126-427d-9a19-4507e22c6b0e)
- [ANDA Submissions | Amendments to Abbreviated New Drug Applications Under GDUFA:  Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/anda-submissions-amendments-to-abbreviated-new-drug-applications-under-gdufa-guidance-for-industry/9fe16cd4-ef07-4dd1-8241-a762f71acbb7)